Search peptides, terms, sources/
Growth hormone axis

Hexarelin

Also known as: Examorelin

Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. In a long-term human study the response faded and IGF-I and body composition did not change.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

3 findings at this grade. 1 further finding at this grade showed no effect and is not counted. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Hexarelin is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials6 human trials

What is Hexarelin?

Hexarelin (also called examorelin) is a synthetic six-amino-acid peptide that triggers growth hormone release and also raises prolactin, ACTH and cortisol. It is not licensed in the UK, and in a long-term human study the growth hormone response faded while IGF-I, body fat, lean mass and bone density showed no significant change.

The human research consists of small studies of hormone response.

Class
Growth hormone-releasing peptide (GHRP) hexapeptide
Origin
Fully synthetic
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Hexarelin work?

Hexarelin is a growth hormone secretagogue that raised growth hormone strongly in human studies, more than GHRH alone but less than ghrelin. With repeated treatment the response was partly blunted, then recovered after treatment stopped. These are hormone measurements, not evidence of a health benefit.

The mechanism in more detail

Hexarelin belongs to the growth hormone-releasing peptides, a class of synthetic growth hormone secretagogues. In human studies it raised growth hormone strongly, more than GHRH alone but less than ghrelin, the body’s own hormone that acts on the same system. Combined with GHRH, a small amount of hexarelin gave a large growth hormone rise.

It is not a selective stimulant. Hexarelin also raised prolactin and cortisol, and in a head-to-head study with GHRP-2 it raised ACTH as well.

With long-term treatment, the growth hormone response to hexarelin was partly blunted (a desensitisation), then recovered after treatment stopped. In that study IGF-I did not change significantly, and body fat, lean mass and bone density were unchanged at the end of treatment. A short-term cardiac study reported a brief rise in the heart’s ejection fraction, also in men who made almost no growth hormone, which the authors took to mean a direct effect on the heart. These are physiological measurements, not evidence of a health benefit.

Classification and structure

Names
Hexarelin; Examorelin
Class
Growth hormone-releasing peptide (GHRP) hexapeptide
Origin
Fully synthetic
Structure
Synthetic hexapeptide (six amino acids).
Routes used in the research
Intravenous injection in most cited human studies; subcutaneous injection in the long-term adult study; nasal route in the paediatric study. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Hexarelin has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
24000

1 of the findings graded Limited showed no effect, so it is not counted in the evidence grade at the top of the page.

Amount-dependent GH, cortisol, prolactin Limited

In a randomised study of healthy men, intravenous hexarelin raised growth hormone, prolactin and cortisol, and the size of the rise grew with the amount given up to a plateau. Hexarelin combined with GHRH gave a large growth hormone release with only a moderate prolactin rise and no cortisol rise.

Study type
Human trial
Population
Human healthy adult men
Source
1 Massoud et al., 1996

Limitation: Short hormone-response study in healthy men.

Limitations in full

Short hormone-response study in healthy men. The abstract does not give the number of subjects. It measures hormone levels, not any health outcome.

Compared with ghrelin and GHRH Limited

In 7 healthy young men, hexarelin raised growth hormone more than GHRH alone (peak about 68 versus 27 micrograms per litre) but less than ghrelin (about 92). Ghrelin also raised prolactin, ACTH and cortisol more than hexarelin did. Adding hexarelin did not change ghrelin's hormone effects.

Study type
Human trial
Population
Human healthy young men aged 24 to 32, 7 participants
Source
2 Arvat et al., 2001

Limitation: Seven men.

Limitations in full

Seven men. The main subject is ghrelin; hexarelin is one comparator. It measures hormone levels only.

Long-term therapy, no benefit shown Limited No effect shown

In a long-term study of repeated hexarelin treatment in adults, the growth hormone response to a test injection fell over the first weeks and came back to the starting level once treatment stopped. IGF-I and IGFBP-3 did not change significantly. Body fat, lean mass and bone mineral density showed no significant change at the end of treatment. The authors concluded that the effect on the growth hormone and IGF-I axis appeared minimal.

Study type
Human trial
Population
Human adults (number and type not stated in the abstract)
Source
3 Rahim et al., 1998

Limitation: The abstract does not state how many people took part or whether there was a control group.

Limitations in full

The abstract does not state how many people took part or whether there was a control group. Only the abstract was read. Single study, not independently replicated.

Children, desensitisation, no control group Preliminary

In 7 prepubertal children with short stature given hexarelin by nasal route for several months, the growth hormone response to hexarelin fell sharply and partly recovered after treatment stopped. Growth rate rose from 5.3 to 7.4 cm per year, but there was no control group, so the rise cannot be credited to hexarelin.

Study type
Human trial
Population
Human prepubertal children with constitutional short stature, mean age 7.6 years, 7 participants
Source
4 Klinger et al., 1996

Limitation: Seven children, no comparison group.

Limitations in full

Seven children, no comparison group. Children grow anyway, so the change in growth rate cannot be attributed to the peptide.

Brief rise in heart ejection fraction Preliminary

In 7 men with growth hormone deficiency and 9 controls, intravenous hexarelin raised the proportion of blood the left ventricle pumps out (ejection fraction) in both groups, with no change in blood pressure, cardiac output or catecholamines. The rise also occurred in the men who made almost no growth hormone, so the authors proposed it is independent of growth hormone and mediated by receptors in the heart muscle.

Study type
Human trial
Population
Human adult men: 7 with growth hormone deficiency and 9 controls
Source
5 Bisi et al., 1999

Limitation: Sixteen men and a brief change in one measurement.

Limitations in full

Sixteen men and a brief change in one measurement. It is not a trial of heart health. The receptor explanation is the authors' proposal, not a demonstrated mechanism.

Head-to-head with GHRP-2 Limited

In seven young volunteers given each compound in separate sessions, hexarelin and GHRP-2 produced similar, large rises in growth hormone, and both raised prolactin, ACTH and cortisol. The study measured hormone levels only.

Study type
Human trial
Population
Human young adult volunteers (sex not stated in the abstract), 7 participants
Source
6 Arvat et al., 1999

Limitation: Seven volunteers in short sessions.

Limitations in full

Seven volunteers in short sessions. Hexarelin and GHRP-2 were comparators for a third compound.

What safety findings have been reported?

2 safety findings are recorded for Hexarelin. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Raises cortisol and prolactin

In healthy men, intravenous hexarelin raised prolactin and cortisol along with growth hormone, in step with the amount given. The study was a hormone-response study and was not designed to look for harm.

Source
1 Massoud et al., 1996

Also raises ACTH

In a head-to-head study in seven volunteers, hexarelin raised ACTH, cortisol and prolactin as well as growth hormone, with responses similar to GHRP-2.

Source
6 Arvat et al., 1999

What is Hexarelin's UK regulatory status?

Marketing authorisation
No UK marketing authorisation found. Not a licensed medicine. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for hexarelin or examorelin.
Prescription status
Not applicable, no licensed UK product was found to classify.
Medicine class
Not classified as a licensed medicine in the UK.
MHRA position
No hexarelin-specific MHRA notice was identified in this review. The review did not include a systematic search of MHRA enforcement releases. Supplying an unlicensed product for human use as a medicine falls under the Human Medicines Regulations 2012.
Authorised use
None.
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework. In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names examorelin (hexarelin) under S2.2.4, growth hormone secretagogues and growth hormone-releasing peptides.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Hexarelin is recorded as not licensed in the UK (checked 14 November 2026).

References

7 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Massoud AF, Hindmarsh PC, Brook CG (1996). Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. Journal of Clinical Endocrinology and MetabolismHuman clinical trial, RCT · DOI 10.1210/jcem.81.12.8954038 · PMID 8954038 · Original ↗
  2. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E (2001). Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology and MetabolismHuman clinical trial, RCT · DOI 10.1210/jcem.86.3.7314 · PMID 11238504 · Original ↗
  3. Rahim A, O'Neill PA, Shalet SM (1998). Growth hormone status during long-term hexarelin therapy. Journal of Clinical Endocrinology and MetabolismHuman clinical trial · DOI 10.1210/jcem.83.5.4812 · PMID 9589671 · Original ↗
  4. Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z (1996). Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. European Journal of EndocrinologyHuman clinical trial · DOI 10.1530/eje.0.1340716 · PMID 8766941 · Original ↗
  5. Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Aimaretti G, Pelosi E, Del Rio G, Muccioli G, Ong H, Boghen MF, Deghenghi R, Ghigo E (1999). Cardiac effects of hexarelin in hypopituitary adults. European Journal of PharmacologyHuman clinical trial · DOI 10.1016/s0014-2999(99)00537-3 · PMID 10528131 · Original ↗
  6. Arvat E, Di Vito L, Lanfranco F, Broglio F, Giordano R, Benso A, Muccioli GP, Deghenghi R, Ghigo E (1999). Tyr-Ala-hexarelin, a synthetic octapeptide, possesses the same endocrine activities of hexarelin and GHRP-2 in humans. Journal of Endocrinological InvestigationHuman clinical trial, RCT · DOI 10.1007/bf03350886 · PMID 10195374 · Original ↗
  7. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Hexarelin

What is Hexarelin?

Hexarelin (also called examorelin) is a synthetic six-amino-acid peptide that triggers growth hormone release and also raises prolactin, ACTH and cortisol. It is not licensed in the UK, and in a long-term human study the growth hormone response faded while IGF-I, body fat, lean mass and bone density showed no significant change. Read what it is.

Is Hexarelin licensed in the UK?

PeptGuru records Hexarelin's UK status as: Not licensed in the UK. No UK marketing authorisation found. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Hexarelin show?

PeptGuru records 6 research findings for Hexarelin: 6 from human trials. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Hexarelin?

2 safety findings are recorded, including: raises cortisol and prolactin; also raises ACTH. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Hexarelin?

All 7 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · Hexarelin added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • GHRP-2Pralmorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-6Growth hormone-releasing…

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • IpamorelinIPA

    Synthetic growth hormone secretagogue studied for growth hormone release. Not licensed in the UK; human evidence is one small pharmacokinetic study.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • SermorelinSermorelin acetate

    Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare Hexarelin with GHRP-2

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.